Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
BRAF V600E
Cancer:
Pancreatic Adenocarcinoma
Drug:
Mekinist (trametinib)
(
MEK inhibitor
) +
Tafinlar (dabrafenib)
(
BRAF inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
NCCN
Published date:
12/06/2022
Excerpt:
Pancreatic Adenocarcinoma...Other Recommended Regimens...Dabrafenib + trametinib (if BRAF V600E mutation positive)...
Evidence Level:
Sensitive: C1 - Off-label
(Approved for Non Small Cell Lung Cancer)
New
Excerpt:
TAFINLAR is indicated, in combination with trametinib, for...the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login